Results 21 to 30 of about 35,120,764 (296)

Immunotherapy With Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors in Patients With Advanced Non–Small Cell Lung Cancers: A Multicenter, Retrospective Analysis [PDF]

MedComm
This multicenter retrospective study analyzed data from 1266 patients with advanced non–small cell lung cancer (NSCLC) across five leading hospitals in China. The aim was to evaluate survival outcomes and safety profiles of programmed cell death 1 (PD‐1)
Jiadi Gan, Kaixin Lei, Tao Chang, Juan Wang, Ruiyuan Yang, Quanling Kong, Jingyi Yuan, Wenjun Meng, Yalun Li, Lina He, Jiaoming Li, Zeng Yan, Bojiang Chen, Weimin Li   +13 more
doaj   +2 more sources

Malaria ookinetes exhibit multiple markers for apoptosis-like programmed cell death in vitro. [PDF]

, 2009
Background: A wide range of unicellular eukaryotes have now been shown to undergo a form of programmed cell death (PCD) that resembles apoptosis; exhibiting morphological and, in some cases, biochemical markers typical of metazoans. However, reports that
Arambage, S.C., Karen M Grant, Grant, Karen M., Pardo, Ian, Hilary Hurd, Grant, K.M., Hurd, Hilary, Ranford-Cartwright, Lisa, Ian Pardo, Lisa Ranford-Cartwright, Hurd, H., Pardo, I., Shashini C Arambage, Arambage, Shashini C., Ranford-Cartwright, L.C., Arambage Shashini C, Ranford-Cartwright Lisa, Pardo Ian, Grant Karen M, Hurd Hilary   +19 more
core   +5 more sources

Expression of PD-1 and PD-L1 in Breast Carcinoma: Research Protocol for a Cohort Study [PDF]

Journal of Clinical and Diagnostic Research, 2023
Introduction: Breast cancer is the most common malignant tumour and the leading cause of cancer-related death in women is breast cancer. The Immunohistochemistry (IHC) method utilised antigens and antibodies to interact to identify cellular or tissue
Shreya Ghosh, Jayant S Makarande, Sunita Vagha, Anil K Agrawal, Sahitya Vodithala   +4 more
doaj   +1 more source

Liver immune-related adverse effects of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: A propensity score matched study with competing risk analyses [PDF]

, 2022
Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors, major classes of immune checkpoint inhibitors, are increasingly prescribed for different cancers.
Wai, A K C, Ng, K, Zhang, Q, Yoo, J W, Liu, T, Tse, G, Zhou, J, Dee, E C, Chau, Y-L A, Lee, S   +9 more
core   +1 more source

PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients [PDF]

Journal of Pathology and Translational Medicine, 2017
Background Programmed death ligand 1 (PD-L1) in tumor cells is known to promote immune escape of cancer by interacting with programmed cell death 1 (PD-1) in tumor infiltrating immune cells.
Jiheun Han, Yongkil Hong, Youn Soo Lee
doaj   +1 more source

Programmed Cell Death Ligand 1 Expression in Osteosarcoma [PDF]

Cancer Immunology Research, 2014
Abstract Programmed cell death ligand 1 (PDL1, also known as B7H1) is a cell-surface protein that suppresses the cytotoxic CD8+ T-cell–mediated immune response. PDL1 expression and its clinical relevance in sarcomas are not well understood.
Jacson K, Shen, Gregory M, Cote, Edwin, Choy, Pei, Yang, David, Harmon, Joseph, Schwab, G Petur, Nielsen, Ivan, Chebib, Soldano, Ferrone, Xinhui, Wang, Yangyang, Wang, Henry, Mankin, Francis J, Hornicek, Zhenfeng, Duan   +13 more
openaire   +2 more sources

An update on immunotherapy with PD-1 and PD-L1 blockade [PDF]

Yeungnam University Journal of Medicine, 2021
Cancer is the leading cause of death and is on the rise worldwide. Until 2010, the development of targeted treatment was mainly focused on the growth mechanisms of cancer.
Sung Ae Koh
doaj   +1 more source

Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis [PDF]

, 2022
Background Programmed death-1 (PD-1) and programmed death- ligand 1 (PD-L1) inhibitors, such as pembrolizumab, nivolumab and atezolizumab, are major classes of immune checkpoint inhibitors that are increasingly used for cancer treatment.
Yunlong Xia, Gary Tse, Sharen Lee, Lei Yang, Jiandong Zhou, Tong Liu, Yuhui Zhang, Kelvin King Hei Bao, Ian Chi Kei Wong, Qingpeng Zhang, Ishan Lakhani, Wing Tak Wong   +11 more
core   +1 more source

Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: a case report

BMC Pulmonary Medicine, 2021
Background Immune checkpoint inhibitors have potential applications in treating various cancers but are associated with immune-related adverse events, such as inflammation, in a wide range of organs; however, allergic inflammation caused by these agents ...
Masanori Harada, Hyogo Naoi, Kazuyo Yasuda, Yutaro Ito, Namio Kagoo, Tsutomu Kubota, Koshiro Ichijo, Eisuke Mochizuki, Masahiro Uehara, Shun Matsuura, Masaru Tsukui, Naoki Koshimizu   +11 more
doaj   +1 more source

Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study

Surgery Open Science, 2021
Background: Inhibition of the programmed death ligand 1, programmed death 1 pathway has been successfully used for treatment of multiple advanced adult cancers. However, its use in pediatric osteosarcoma is still in its infancy.
Nicholas J. Skertich, MD, Fei Chu, MD, PhD, Imad AM Tarhoni, MD, PhD, Stephen Szajek, MS, Jeffrey A. Borgia, PhD, Mary Beth Madonna, MD   +5 more
doaj   +1 more source